Walleye Capital LLC recently announced the acquisition of new stake in Processa Pharmaceuticals Inc (NASDAQ:PCSA). The institutional investor has increased its shareholding in the Healthcare company by 14.36% to 0.42 million shares with purchase of 52640.0 shares. This fresh investment now brings its stake to 1.70% valued currently at $0.14 million. In addition, Geode Capital Management LLC raised its holdings by 83843.0 to 0.15 million shares. And Renaissance Technologies LLC has lifted its position by 18.72% or 8500.0 shares – to 53900.0 shares.
Currently, there are 1.23M common shares owned by the public and among those 0.94M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 26 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 26 of these insider trades were purchases, accounting for 840,132 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
However, the script later moved the day high at 4.3900, down -28.04%. The company’s stock has a 5-day price change of -18.44% and -44.39% over the past three months. PCSA shares are trading -45.16% year to date (YTD), with the 12-month market performance down to -81.83% lower. It has a 12-month low price of $2.02 and touched a high of $25.40 over the same period. PCSA has an average intraday trading volume of 1.29 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -34.86%, -58.89%, and -59.49% respectively.
Institutional ownership of Processa Pharmaceuticals Inc (NASDAQ: PCSA) shares accounts for 5.65% of the company’s 1.23M shares outstanding. Mutual fund holders own 24.79%, while other institutional holders and individual stakeholders account for 4.20% and 1.45% respectively.
It has a market capitalization of $4.51M and a beta (3y monthly) value of 0.48. The earnings-per-share (ttm) stands at -$23.24. Price movements for the stock have been influenced by the stock’s volatility, which stands at 35.61% over the week and 20.33% over the month.
Analysts forecast that Processa Pharmaceuticals Inc (PCSA) will achieve an EPS of -$1.6 for the current quarter, $0 for the next quarter and -$7 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.6 while analysts give the company a high EPS estimate of -$1.6. Comparatively, EPS for the current quarter was -$7.4 a year ago. Earnings per share for the fiscal year are expected to increase by 75.88%, and 14.63% over the next financial year. EPS should grow at an annualized rate of 15.00% over the next five years, compared to -32.30% over the past 5-year period.
